PIN1 and hepatocellular carcinoma: Wang et al. demonstrated that inhibition of Pin1 can reverse acquired resistance to regorafenib in HCC in part by inhibiting EMT through the Gli1/Snail/E-cadherin pathway (Zhang et al., 2021b).